Pages that link to "Q34895335"
Jump to navigation
Jump to search
The following pages link to Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. (Q34895335):
Displaying 50 items.
- Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (Q22241650) (← links)
- Mitoxantrone for multiple sclerosis (Q24202866) (← links)
- Natalizumab for relapsing remitting multiple sclerosis (Q24235861) (← links)
- Mitoxantrone for multiple sclerosis (Q24245404) (← links)
- Natalizumab: A new treatment for relapsing remitting multiple sclerosis (Q24683014) (← links)
- Multiple sclerosis (Q26995437) (← links)
- Development of oral immunomodulatory agents in the management of multiple sclerosis (Q28388704) (← links)
- Switching multiple sclerosis patients with breakthrough disease to second-line therapy (Q33815455) (← links)
- Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. (Q33899881) (← links)
- Toxicities of immunosuppressive treatment of autoimmune neurologic diseases (Q34257903) (← links)
- Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. (Q34535269) (← links)
- Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study (Q34810005) (← links)
- Stem cell transplantation for multiple sclerosis: What is the evidence? (Q35558523) (← links)
- Mitoxantrone: a review of its use in multiple sclerosis (Q35747877) (← links)
- A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis (Q35753383) (← links)
- Mitoxantrone as a potential therapy for primary progressive multiple sclerosis (Q35818165) (← links)
- Management of secondary-progressive multiple sclerosis (Q35843538) (← links)
- Escalating immunotherapy of multiple sclerosis--new aspects and practical application. (Q35981192) (← links)
- Mitoxantrone (Novantrone) in multiple sclerosis: new insights (Q36107235) (← links)
- The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks? (Q36407273) (← links)
- Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management (Q36419566) (← links)
- Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding. (Q36688987) (← links)
- Drug-induced cardiovascular disorders (Q36920662) (← links)
- Immunosuppressive agents in multiple sclerosis (Q36963189) (← links)
- Current and future therapies for multiple sclerosis (Q37287769) (← links)
- Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations (Q37324279) (← links)
- Immunosuppression followed by immunomodulation (Q37387960) (← links)
- Multiple sclerosis: an update for oral health care providers (Q37589026) (← links)
- Quality of life in multiple sclerosis: effects of current treatment options (Q37710122) (← links)
- Adherence to recommended dosing and monitoring for mitoxantrone in patients with multiple sclerosis: a healthcare claims database study supplemented with medical records--the RETRO study (Q37718137) (← links)
- Current and future disease-modifying therapies in multiple sclerosis (Q37747735) (← links)
- Current and Future Role of Interferon Beta in the Therapy of Multiple Sclerosis (Q37793141) (← links)
- A critical appraisal of treatment decisions in multiple sclerosis--old versus new. (Q37862062) (← links)
- Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. (Q38164425) (← links)
- Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited? (Q38228300) (← links)
- Protective Effects of Chrysin Against Drugs and Toxic Agents (Q38685201) (← links)
- Comparative study of mitoxantrone efficacy profile in patients with relapsing—remitting and secondary progressive multiple sclerosis (Q42920232) (← links)
- Mitoxantrone for worsening multiple sclerosis: Tolerability, toxicity, adherence and efficacy in the clinical setting (Q42930829) (← links)
- Mitoxanthrone in the therapy of multiple sclerosis (Q44613381) (← links)
- Non-Invasive Functional and Biochemical Assessment of Mitoxantrone Cardiotoxicity in Patients with Multiple Sclerosis (Q44630598) (← links)
- Aggressive multiple sclerosis. Definition and specific therapeutic indication (Q44804231) (← links)
- Heart transplantation in a patient with multiple sclerosis and mitoxantrone-induced cardiomyopathy (Q44890279) (← links)
- A nurse-led, patient-centred mitoxantrone service in neurology (Q45153766) (← links)
- Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients (Q45354300) (← links)
- Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? (Q46104696) (← links)
- The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients (Q46415609) (← links)
- Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. (Q46441000) (← links)
- Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients (Q46976270) (← links)
- [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action]. (Q52855510) (← links)
- Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis (Q56986554) (← links)